CPMV · XBRL financial data

Mosaic ImmunoEngineering financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CPMV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	—	1,456	1,048	435	184	64
General and administrative	—	2,045	1,579	964	696	552
Total operating expenses	—	3,501	2,628	1,400	880	616
Operating income (loss)	—	(3,501)	(2,628)	(1,400)	(880)	(616)
Interest expense	—	—	—	0	7	10
Income tax expense (benefit)	—	2	2	2	2	2
Net income (loss)	—	(3,684)	(2,381)	(1,008)	(922)	(688)
Earnings per share, basic USD per share	—	(0.55)	(0.33)	(0.14)	(0.13)	(0.10)
Earnings per share, diluted USD per share	—	(0.55)	(0.33)	(0.14)	(0.13)	(0.10)
Weighted average shares, basic thousands of shares	—	6,713	7,236	7,236	7,236	7,236
Weighted average shares, diluted thousands of shares	—	6,713	7,236	7,236	7,236	—

Fiscal years (CPMV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	353	226	221	156	115	4
Prepaid and other current assets	—	—	—	—	27	16
Total current assets	458	269	261	180	142	20
Total assets	458	269	261	180	142	20
Accounts payable	86	114	133	118	135	133
Accrued liabilities	661	724	585	642	647	655
Total current liabilities	880	2,333	3,918	4,733	5,537	6,030
Total liabilities	880	3,069	5,146	6,051	6,930	7,496
Accumulated deficit	(843)	(4,527)	(6,908)	(7,916)	(8,838)	(9,526)
Total stockholders' equity	(423)	(2,799)	(4,885)	(5,871)	(6,788)	(7,476)
Total liabilities and equity	458	269	261	180	142	20
Common shares outstanding (cover page) thousands of shares	7,228	7,241	7,242	7,242	7,242	7,242

Fiscal years (CPMV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	(3,684)	(2,381)	(1,008)	(922)	(688)
Stock-based compensation	—	1,308	295	22	5	0
Net cash from operating activities	—	(679)	(690)	(497)	(241)	(111)
Net cash from investing activities	—	28	343	433	0	—
Proceeds from issuing common stock	—	0	—	—	—	—
Proceeds from long-term debt	—	—	—	0	270	0
Net cash from financing activities	—	525	342	0	200	0

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
China Foods Holdings	16	0	(94)*	20.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1,629	not reported	(1,394)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Twinlab Consolidated Holdings	13	not reported	(907)*	259.1M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Regen BioPharma	0.2	59	(24)*	1.7B	0.0 quarters	Q3 FY26 10-QJun 30, 2026
Evofem Biosciences	285	2,633	(3,140)*	132.5M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.